Results 121 to 130 of about 98,414 (282)

Response to Comment on "Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials". [PDF]

J Diabetes Sci Technol, 2022
Cobelli C, Dalla Man C.
europepmc   +1 more source

Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. [PDF]

, 2018
Purpose: The retinoblastoma tumor suppressor (RB), a key regulator of cell-cycle progression and proliferation, is functionally suppressed in up to 50% of non-small cell lung cancer (NSCLC).
Addya, Sankar, Bhardwaj, Anshul, Birbe, Ruth, Chellappagounder, Thangavel, Den, Robert B., Dicker, Adam P., Ertel, Adam, Ettickan, Boopathi, Haber, Alex, Knudsen, Karen E., Liu, Yi, McNair, Christopher, Perepelyuk, Maryna, Salvino, Joseph M., Shoyele, Sunday   +14 more
core   +1 more source

QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Advanced Science, EarlyView.
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V. Laurents, Mariano Carrión‐Vázquez   +8 more
wiley   +1 more source

Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials. [PDF]

J Diabetes Sci Technol, 2022
Cobelli C, Dalla Man C.
europepmc   +1 more source

De Novo Design and Directed Evolution Refinement of Mirror‐Image Protein Binders Targeting Interleukin‐4

Advanced Science, EarlyView.
This study presents the de novo design and directed evolution of a mirror‐image D‐protein inhibitor targeting human interleukin‐4 (IL‐4). The engineered molecule exhibits nanomolar binding affinity for IL‐4 and effectively inhibits IL‐4–mediated signaling.
Liqing Xu, Yuxiang Ren, Tongyue Wang, Hongyong Li, Yue Yao, Lei Liu, Ke Sun, Peilong Lu   +7 more
wiley   +1 more source

In Silico Evaluation of Algorithm-Based Clinical Decision Support Systems: Protocol for a Scoping Review

JMIR Research Protocols
BackgroundIntegrating algorithm-based clinical decision support (CDS) systems poses significant challenges in evaluating their actual clinical value.
Michael Dorosan, Ya-Lin Chen, Qingyuan Zhuang, Shao Wei Sean Lam   +3 more
doaj   +1 more source

Causal Prediction of TP53 Variant Pathogenicity Using a Perturbation‐Informed Protein Language Model

Advanced Science, EarlyView.
A TP53‐specific predictor, CaVepP53, is developed by fine‐tuning ESMC on experimentally validated variants, quantifying pathogenicity via Euclidean distances. It outperforms general‐purpose models and extends to five cancer genes, enabling interpretable variant classification for precision medicine.
Huiying Chen, Yang Zhao, Boqiang Hu, Wuke Wang, Minfang Song, Annabeth Xinyu Zhao, Xiangyang Li, Gefei Wang, Yanfen Wang, Weiyan Zheng, Xinpeng Zhang, Xia Lin, Yanbin Yin, Xingxu Huang, Jinfang Zheng, Tingbo Liang   +15 more
wiley   +1 more source

Clinical modeling of motor function to predict treatment efficacy and enable in silico treatment comparisons in infantile‐onset Pompe disease

CPT: Pharmacometrics & Systems Pharmacology
Infantile‐onset Pompe disease (IOPD) is a rare, deadly, quickly‐progressing degenerative disease. Even with life‐sustaining treatment (e.g., alglucosidase alfa [ALGLU]), many patients experience continued motor impairment.
Fatiha Rachedi, Rana Jreich, Susan Sparks, Atef Zaher, Kristina an Haack, Alicia Granados, Zhaoling Meng   +6 more
doaj   +1 more source

The Changing Nature of Pharmaceutical R&D - Opportunities for Asia? [PDF]

During the 1990''s, the pharmaceutical R&D process has witnessed tremendous technological changes. The emergence of new tools like ''combinatorial chemistry'', ''high throughput screening'' and the in-creasing use of computer-aided in silico experiments ...
Mahlich ,Jörg C., Roediger-Schluga,Thomas   +1 more
core   +1 more source

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source